Free Biopharma Daily Stock Updates - 05/25/21

$XBI $124.3 -1.6%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$IBRX +0.3% ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa. source

$XNCR -2.5% Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19. source

$MRNA +3.1% Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June. source

Pipeline Updates

$LRMR -10.6% Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing. source

$TVTX -1.2% Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis. source

$PRVB +26.8% Provention Bio Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Teplizumab. source

$EYEN +2.1% Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia. source

$MBRX -1.4% Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases. source

$CDMO -1.3% Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl). source

$CRBP +5.3% Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress. source

$ORIC -0.7% ORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel. source

$KROS +0.2% Keros Therapeutics Announces Issuance of U.S. Patent for Use of Therapeutic Proteins in Treatment of Musculoskeletal Disorders. source

$PIRS +103.2% Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech. source

$KRON -2.7% Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today. source

$EYPT -0.6% EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD. source

$AUTL -2.7% Autolus Therapeutics Announces an Additional Nature Publication for AUTO1. source

$TGTX -0.6% TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. source

$APLS +2.3% Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH. source

$TXMD -3.3% TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA. source

$TLC +28.7% TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India. source

$TLSA +3.9% Tiziana Life Sci PLC - Trial Initiation in a SPMS Patient with Foralumab. source

$VKTX -11.2% and $ETNB -10.2% Raymond James is downgrading 89bio and Viking Therapeutics following disappointing results from competitor NGM Biopharmaceuticals NASH candidate aldafermin. source

$RETA +7.7% On 5/19/21 Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich’s Ataxia source

$GRCL -15.8% Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June. source

Financial Updates

$NOVN -40.4% Novan Announces 1-for-10 Reverse Stock Split. source

$ANVS -12.9% On 5/23/21 Annovis Bio, Inc. Announces Pricing of Public Offering. source

---

Posted by FS